Komori
Noevir Holdings (4928) · InitiativeRestated

Expenditure on Research and Development Activities

First written in FY2016-Q3. 25 of 35 entries say "Restated". Latest entry: FY2026-H1.

35entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016-Q3 – FY2017-Q3RestatedFY2021-Q1 – FY2022-Q32016: 120162017: 420172018: 420182019: 420192020: 420202021: 420212022: 420222023: 420232024: 320242025: 220252026: 1
Same theme, other companies
Continuation of R&D activities with no change in statusA theme 217 companies write about · 0 as a headwind · 206 as a tailwind

92 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 221 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「Total research and development expenses for the six-month interim consolidated period were ¥563 million. There were no material changes in the status of the Group's research and development activities during the six-month interim consolidated period.」

    Research and development expenses of ¥563 million were recorded, and the explanation that there have been no material changes in the status of research and development activities continues.
  2. FY2025AdvancedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥1,134 million, comprising ¥1,009 million for the Cosmetics segment and ¥125 million for the Pharmaceuticals and Foods segment.」

    Research and development expenses increased from ¥1,066 million in the previous fiscal year to ¥1,134 million. Research continued at the Tokyo Research Institute, the Shiga Research Institute and plant research centers, bringing multiple products and basic research results to fruition.
  3. FY2025-H1RestatedAnnual report

    「Total research and development expenses for the six-month interim consolidated period were ¥516 million. There were no material changes in the status of the Group's research and development activities during the six-month interim consolidated period.」

    The disclosure states that the company recorded ¥516 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  4. FY2024AdvancedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥1,066 million, comprising ¥943 million for the Cosmetics segment and ¥122 million for the Pharmaceuticals and Foods segment.」

    Research and development expenses increased from ¥1,029 million in the previous fiscal year to ¥1,066 million, and the company continued research and development activities involving research centers, plant research and external presentations.
  5. FY2024-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥514 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥514 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  6. FY2024-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥252 million.」

    Research and development activities and the recording of research and development expenses continued. Research and development expenses increased from ¥239 million in the same period of the previous year to ¥252 million.
  7. FY2023AdvancedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥1,029 million, comprising ¥900 million for the Cosmetics segment and ¥128 million for the Pharmaceuticals and Foods segment.」

    Research and development expenses decreased from ¥1,063 million in the previous fiscal year, while the company brought multiple new products and research results concerning plant extracts, skin aging, immunity and beauty to fruition.
  8. FY2023-Q3RestatedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥763 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥763 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  9. FY2023-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥493 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥493 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  10. FY2023-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥239 million. There were no material changes in the status of the Group's research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥239 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  11. FY2022AdvancedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥1,063 million, comprising ¥929 million for the Cosmetics segment and ¥133 million for the Pharmaceuticals and Foods segment.」

    Research and development expenses increased from ¥1,041 million in the previous fiscal year to ¥1,063 million. Research and development using research centers, the company's own research facilities and collaboration with external institutions also continued.
  12. FY2022-Q3RestatedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥771 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥771 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  13. FY2022-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥494 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥494 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  14. FY2022-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥252 million. There were no material changes in the status of the Group's research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥252 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  15. FY2021Slight decline in research and development expenses; research results brought to fruitionAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥1,041 million, comprising ¥905 million for the Cosmetics segment and ¥135 million for the Pharmaceuticals and Foods segment.」

    Research and development expenses decreased slightly from ¥1,065 million in the previous fiscal year to ¥1,041 million, while the disclosure gives specific details of product development and basic research results.
  16. FY2021-Q3RestatedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥786 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥786 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  17. FY2021-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥518 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥518 million in research and development expenses and continues to explain that there were no material changes in the status of research and development activities.
  18. FY2021-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥255 million. There were no material changes in the status of the Group's research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」

    The disclosure states that the company recorded ¥255 million in research and development expenses and continues to explain that there were no material changes in research and development activities.
  19. FY2020AdvancedAnnual report

    「The Group's Comprehensive Research Institute in Shiga Prefecture is responsible for developing cosmetic, pharmaceutical and food products, while the Tokyo Research Institute promotes basic and clinical research. The Group has expanded its research fields through active collaboration with external institutions and strengthened its technological capabilities. Total research and development expenses for the consolidated fiscal year were ¥1,065 million, and」

    The company continued collaboration between its research centers and external institutions and brought multiple new products and basic research results to fruition. Research and development expenses were ¥1,065 million.
  20. FY2020-Q3RestatedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥777 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥777 million and that there were no material changes in research and development activities.
  21. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥522 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥522 million and that there were no material changes in research and development activities.
  22. FY2020-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥231 million. There were no material changes in the status of the Group's research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥231 million and that there were no material changes in research and development activities.
  23. FY2019AdvancedAnnual report

    「Total research and development expenses for the consolidated fiscal year were ¥1,097 million, comprising ¥972 million for the Cosmetics segment and ¥125 million for the Pharmaceuticals and Foods segment.」

    Research and development expenses increased from ¥1,046 million in the previous fiscal year to ¥1,097 million, while the company continued developing cosmetic, pharmaceutical and food products.
  24. FY2019-Q3RestatedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥795 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥795 million and that there were no material changes in research and development activities.
  25. FY2019-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥526 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥526 million and that there were no material changes in research and development activities.
  26. FY2019-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥244 million. There were no material changes in the status of the Group's research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥244 million and that there were no material changes in research and development activities.
  27. FY2018AdvancedAnnual report

    「The Group's Comprehensive Research Institute in Shiga Prefecture develops cosmetic, pharmaceutical and food products, while the Tokyo Research Institute promotes basic research into materials and clinical research on products. The Group has expanded its research fields and strengthened its research and development structure by enhancing its expertise and actively collaborating with external institutions. Total research and development expenses for the consolidated fiscal year were ¥1,046 million, and」

    The disclosure describes the division of responsibilities among research centers, collaboration with external parties and the strengthening of expertise, as well as full-year research and development expenses and specific new products and research results.
  28. FY2018-Q3RestatedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥768 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥768 million and that there were no material changes in research and development activities.
  29. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥519 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥519 million and that there were no material changes in research and development activities.
  30. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥249 million. There were no material changes in the status of the Group's research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥249 million and that there were no material changes in research and development activities.
  31. FY2017AdvancedAnnual report

    「Research and development expenses for the consolidated fiscal year were ¥1,134 million.」

    The company continued its research and development activities and developed new cosmetic, pharmaceutical and food products. Research and development expenses were ¥1,134 million.
  32. FY2017-Q3RestatedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥841 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥841 million and that there were no material changes in research and development activities.
  33. FY2017-Q2RestatedAnnual report

    「Total research and development expenses for the six months ended the second quarter of the current consolidated fiscal year were ¥565 million. There were no material changes in the status of the Group's research and development activities during the six months ended the second quarter of the current consolidated fiscal year.」

    The disclosure states that research and development expenses were ¥565 million and that there were no material changes in research and development activities.
  34. FY2017-Q1RestatedAnnual report

    「Total research and development expenses for the three months ended the first quarter of the current consolidated fiscal year were ¥270 million. There were no material changes in the status of the Group's research and development activities during the three months ended the first quarter of the current consolidated fiscal year.」

    The disclosure states that research and development activities continued and gives the amount spent during the quarter, while explaining that there were no material changes in the status of those activities.
  35. FY2016-Q3First statedAnnual report

    「Total research and development expenses for the nine months ended the third quarter of the current consolidated fiscal year were ¥881 million.」

    The total research and development expenses for the cumulative third quarter were disclosed.
Moved together

"Strengthening the R&D Structure and Collaboration with Academic Institutions" moved the same way as this thread, in the same document, in 7 of its 35 moves.

766654★123456
  1. ★This thread
  2. 1Strengthening the R&D Structure and Collaboration with Academic Institutions7×
  3. 2Cosmetics Business Revenue and Profit Growth6×
  4. 3Investment in production facilities6×
  5. 4Expanding the Cosmetics Customer Base Through New Products and Existing Series6×
  6. 5Shareholder Returns Through Dividends5×
  7. 6Increase in cash flows from operating activities4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Noevir Holdings's next results are scheduled for 2026-11-10. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.